Details

Autor(en) / Beteiligte

• Somasegar, Sahana
• Reddy, Ravali A.
• Chow, Stephanie
• Dorigo, Oliver
• Renz, Malte
• Karam, Amer

Titel

Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis

Ist Teil von

• Gynecologic oncology, 2024-05, Vol.184, p.190-197

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• To characterize trends in ovarian, fallopian tube, and primary peritoneal cancer incidence and incidence-based mortality based on histology and site of origin. We obtained age-adjusted incidence and incidence-based mortality for patients with ovarian, fallopian tube, and primary peritoneal cancer from 2000 to 2019 from the US SEER 17 database. Joinpoint 4.9.1.0 was used to characterize log-linear time trends. The incidence and incidence-based mortality of all cancers trended down during the study period. The incidence of epithelial cancers decreased from 2004 to 2019 (AAPC −1.2%, p < 0.001), including that of high-grade (2006–2019: APC −1.2%, p < 0.05) and low-grade (2003–2019: APC −2.4%, p < 0.05) epithelial cancers. There was no change in incidence or incidence-based mortality for ovarian stromal and germ cell cancers. There has been a decrease in the incidence and incidence-based mortality of ovarian, fallopian tube, and primary peritoneal cancer, primarily due to reductions in advanced stage epithelial cancers originating in the ovary, fallopian tube, or peritoneum. •There has been an overall decline in the incidence and incidence-based mortality of ovarian cancer over a 15-year period.•This decline is primarily driven by declines in epithelial cancers arising in the ovaries, fallopian tube, or peritoneum.•There are fewer patients diagnosed with epithelial cancers, particularly advanced stage disease.•Contributing factors include advances in early detection, more risk-reducing surgeries, and stage migration.•Other factors include improved treatment options and changes in oral contraceptive and postmenopausal hormone therapy use.